Source comparison
Calculate MK-677 Dosage: Protocol Comparison
Choosing the right dosing protocol depends on research goals, subject baseline health, and acceptable adverse event thresholds. Here's how the standard approaches compare. Standard Growth Hormone Study 20–25mg daily 7 days (50% → 75% → 100%) 18–22% (mostly ede
This comparison does not assign a generated winner or score.
- Choosing the right dosing protocol depends on research goals, subject baseline health, and acceptable adverse event thresholds. Here's how the standard approaches compare.
- Standard Growth Hormone Study
- 20–25mg daily
- 7 days (50% → 75% → 100%)
- 18–22% (mostly edema, lethargy)
- Healthy subjects, GH secretion endpoints, 8–12 week duration
- Optimal balance between efficacy and tolerability for most research applications
- Conservative Metabolic Study
- 10–15mg daily
- 14 days (25% → 50% → 75% → 100%)
- 8–12%
- Subjects with pre-diabetes, insulin resistance, or metabolic syndrome
- Sacrifice some GH amplitude to preserve insulin sensitivity. Required when glucose control is a secondary endpoint
- High-Dose Body Composition
- 25–30mg daily
- 7 days with weekly glucose monitoring
- 35–45%
- Lean mass research, short-duration trials (4–6 weeks), continuous medical oversight
- Maximizes anabolic signal but requires strict adverse event management. Not appropriate for unsupervised protocols
- Sleep Architecture Study
- 10–20mg daily
- 3 days (75% → 100%)
- 10–15%
- Sleep quality endpoints, older populations, evening administration only
- Lower dose reduces daytime lethargy while preserving nocturnal GH pulse enhancement